Plozasiran Injection
NDC Package 70596-1007-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Plozasiran injection is a bulk ingredient utilized for pharmaceutical compounding or manufacturing. This formulation utilizes a injection delivery system. Marketed by Agilent Technologies Inc., this product is identified by NDC 70596-1007.

Identification & Billing

NDC Package Code
70596-1007-1
Package Description
2000 g in 1 BOTTLE
Product Code
70596-1007
11-Digit Billing Format
70596100701

Clinical Specifications

Proprietary Name
Plozasiran
Non-Proprietary Name
Plozasiran
Substance Name
Plozasiran Sodium
Dosage Form
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Active Ingredient(s)
PLOZASIRAN SODIUM 1 g/g

Regulatory & Marketing

Labeler Name
Agilent Technologies Inc.
Product Type
Bulk Ingredient
Marketing Category
BULK INGREDIENT - A category specifying that a product is marketed as a bulk ingredient.
Start Marketing Date
11-18-2025
Listing Expiration
12-31-2027
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70596-1007-1 identifies a specific commercial package of 2000 g in 1 bottle of Plozasiran (UNFINISHED drug), a bulk ingredient labeled by Agilent Technologies Inc.. This injection is formulated for use and contains plozasiran sodium as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Agilent Technologies Inc. on November 18, 2025. The current certification is valid through December 31, 2027.

How is this Agilent Technologies Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70596100701. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
70596-1007-1
11-Digit CMS (5-4-2)
70596-1007-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.